Oruka Therapeutics director plans $2.42M share sale

The notice reports 66,209,699 common shares outstanding, separate from the proposed 25,000-share sale.

Available on EDGAR 11/02/2026 - 04:39 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:39 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) director and officer Lawrence Klein reported an intended sale of 25,000 common shares, with an aggregate market value of $2,421,750, through Morgan Stanley Smith Barney LLC on NASDAQ on November 2, 2026. The notice says the shares were acquired from the issuer through exercise of stock options. It also lists prior sales of 25,000 shares on October 1, 2026, 2,452 shares on September 15, 2026, and 75,000 shares on September 1, 2026.

Key Figures

Proposed shares to be sold: 25,000 shares Aggregate market value: $2,421,750 Shares outstanding: 66,209,699 shares +3 more

6 metrics

Proposed shares to be sold 25,000 shares Approximate sale date November 2, 2026

Aggregate market value $2,421,750 Proposed sale

Shares outstanding 66,209,699 shares Reported in the notice

Prior sale 25,000 shares; $2,090,592.50 October 1, 2026

Prior sale 2,452 shares; $234,680.92 September 15, 2026

Prior sale 75,000 shares; $6,887,490.00 September 1, 2026

Key Terms

Rule 144, 10b5-1 Sales, Exercise of Stock Options

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 Sales financial

"10b5-1 Sales for LAWRENCE KLEIN"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Exercise of Stock Options financial

"Exercise of Stock Options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORKA shares did Lawrence Klein plan to sell?

Lawrence Klein reported an intended sale of 25,000 common shares on November 2, 2026, with an aggregate market value of $2,421,750.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001762583
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Oruka Therapeutics, Inc.
SEC File Number	000-22873
Address of Issuer	855 Oak Grove Avenue Suite 100 Menlo Park CALIFORNIA 94025
Phone	6506067910
Name of Person for Whose Account the Securities are To Be Sold	LAWRENCE KLEIN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	2421750.00	66209699	11/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/02/2026	Exercise of Stock Options	Issuer			25000	11/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for LAWRENCE KLEIN 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	10/01/2026	25000	2090592.50
LAWRENCE KLEIN 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	09/15/2026	2452	234680.92
10b5-1 Sales for LAWRENCE KLEIN 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	09/01/2026	75000	6887490.00

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/14/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Lawrence Klein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)